Présentation de l'entreprise
Cingulate Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops pharmaceutical products utilizing its proprietary drug delivery platform technology to address conditions such as attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's primary asset is its lead product candidate, CTx-1301 (dexmethylphenidate), which represents its core focus for treating these specific neurological and psychiatric disorders. In terms of corporate scale, Cingulate Inc. maintains a market capitalization of $68.03M and employs 14 individuals to execute its research and development strategy. The absence of reported annual revenue figures, combined with a market cap of $68.03M, indicates that the company is in a pre-revenue or early-stage development phase, relying entirely on capital markets and existing cash reserves to fund its scientific advancements rather than generating commercial income from product sales. This financial structure is typical for biotechnology firms that have not yet achieved commercialization of their pipeline assets, positioning the company as a high-risk, high-potential venture dependent on future regulatory approvals and market entry.
Santé financière
The company reports a net income of $-22,449,912 for the trailing twelve months, while revenue is listed as N/A, revealing a significant gap where operating costs and research expenses far exceed any current commercial income. Similarly, the EBITDA stands at $-19,397,214, which further underscores the substantial burn rate associated with developing pharmaceutical products without established sales streams. The free cash flow is recorded at $-10,425,198, indicating that the company is consuming cash reserves rapidly to sustain operations and fund its drug delivery platform technology. Analyzing the margin profile, the gross margin is 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, all of which reflect the lack of revenue and the dominance of developmental costs in the company's financial statements. Regarding liquidity and leverage, the company holds $10.95M in cash against $8.79M in debt, resulting in a debt-to-equity ratio of 350.21, which suggests a highly leveraged balance sheet relative to its equity base. Despite the high debt-to-equity ratio, the current ratio stands at 1.16, indicating that the company possesses sufficient current assets to cover its short-term liabilities, though the margin for error is narrow given the negative cash flow. Return on equity is reported at -450.6% and return on assets at -83.2%, metrics that demonstrate how the company's assets and equity are currently being utilized to generate significant losses rather than returns. These negative return figures highlight the aggressive spending typical of early-stage biotech firms that are prioritizing pipeline development over profitability.
Évaluation de la valorisation
Valuation metrics for Cingulate Inc. present a complex picture due to the lack of profitability, with the P/E ratio (TTM) listed as N/A and a forward P/E of -3.96. The negative forward P/E implies that the market is pricing the stock based on expectations of future earnings that have not yet materialized, rather than current performance. The price-to-book ratio is 16.91, which indicates that the market is valuing the company at a significant premium over its book value, a common occurrence for biotechnology firms where the intellectual property and pipeline potential are valued higher than their tangible assets. Alternative valuation metrics such as the EV/EBITDA of -3.40 and the price-to-sales ratio of N/A further suggest that traditional valuation models are less applicable given the absence of sales and earnings data. Regarding price volatility, the 52-week high is $11.89 and the 52-week low is $3.20, providing a historical range within which the stock has traded over the past year. The beta value of -0.77 is notable, as it indicates an inverse correlation to the broader market, suggesting that the stock price tends to move in the opposite direction of the general market index. This negative beta implies that during periods of market decline, Cingulate's stock may theoretically rise, although the magnitude of such movements depends on specific company news and investor sentiment regarding its drug pipeline.
Growth & Income
Growth metrics for the company are not yet established, as the revenue growth (YoY) is N/A and the earnings growth (YoY) is also N/A. The absence of these figures confirms that the company has not yet reached a stage of consistent commercial expansion where year-over-year growth rates can be calculated. Since the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders. Consequently, the company reinvests all available capital, including its cash reserves and proceeds from financing, directly into its research and development activities to advance its pharmaceutical products. The overall growth and income profile is characterized by a complete reliance on future commercialization success rather than current earnings or dividend distributions. Investors seeking income through dividends would find no utility in this stock, while those focused on capital appreciation must rely on the potential future success of the CTx-1301 product candidate. The lack of historical growth data means that any assessment of future potential is speculative and dependent on the successful execution of the company's drug delivery platform technology.